Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL9551301 | 0.84 | L3MBTL1 (0.39) | HRH4ALDH1A1GAA | |
| Pyridine SCHEMBL19405324 | 0.83 | TSHR (0.53) | TSHRNAPRTTDP1LMNAHRH4 | |
| Pyridine SCHEMBL19514458 | 0.79 | ALDH1A1 (0.49) | TSHRLMNAALDH1A1HPGDKDM4E | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL15264514 | 0.78 | TDP1 (0.47) | TSHRNAPRTTDP1LMNAROCK2 | |
| Dioxane SCHEMBL262902 | 0.77 | TSHR (0.60) | TSHRNAPRTTDP1LMNAHTT | |
| Dioxane SCHEMBL28097100 | 0.77 | TSHR (0.60) | TSHRNAPRTTDP1LMNAHTT | |
| Hydrogen Peroxide SCHEMBL11793831 | 0.77 | — | — | |
| Methyl Alcohol SCHEMBL28612959 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL28636034 | 0.77 | — | — | |
| SCHEMBL4622 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182496-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2024-06-06 | — | — | US | claimed |
| EP-3704100-B1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LTD (IN) | 2023-08-30 | — | — | EP | claimed |
| EP-3737685-B1 | PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LTD (IN) | 2023-03-29 | — | — | EP | claimed |
| CN-112794818-A | Preparation method of N-propylaminoquinolinone and application of N-propylaminoquinolinone in synthesis of abscisic acid agonist AM1 and derivatives thereof | 邵阳学院 | 2021-05-14 | — | — | CN | claimed |
| CN-112778167-A | Method for rapidly preparing N-benzenesulfonyl amino acid ester compound | 邵阳学院 | 2021-05-11 | — | — | CN | claimed |
| US-20210070778-A1 | NOVEL PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2021-03-11 | — | — | US | claimed |
| US-20200262848-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2020-08-20 | — | — | US | claimed |
| US-9932336-B2 | Process for the preparation of apixaban and intermediates thereof | Jubilant Generics Limited (IN) | 2018-04-03 | — | — | US | claimed |
| EP-3212620-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) (IN) | 2017-09-06 | — | — | EP | claimed |
| WO-2016067308-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LIMITED (FORMERLY JUBILANT LIFE SCIENCES DIVISION) (IN) | 2016-05-06 | — | — | WO | claimed |
| US-20240182496-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LIMITED (IN) | 2024-06-06 | — | — | US | disclosed |
| EP-3704100-B1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LTD (IN) | 2023-08-30 | — | — | EP | disclosed |
| US-11708382-B2 | Process for the preparation of highly pure Crisaborole | HALCYON LABS PRIVATE LIMITED (IN) | 2023-07-25 | — | — | US | disclosed |
| EP-3737685-B1 | PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | HALCYON LABS PRIVATE LTD (IN) | 2023-03-29 | — | — | EP | disclosed |
| EP-4119566-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | Halcyon Labs Private Limited (IN) | 2023-01-18 | — | — | EP | disclosed |
| WO-1992020336-A2 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0512865-A2 | Novel cholesterol lowering compounds | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0286145-A2 | 3-Heterocyclylthiomethyl cephalosporins | SANKEI PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-10-12 | — | — | EP | disclosed |
| US-4376203-A | ANTIBIOTIC | ROUSSELL UCLAF (FR) | 1983-03-08 | — | — | US | disclosed |
| US-3941693-A | Solid mineral and regenerant recovery for ion-exchange resins | AEROJET-GENERAL CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070778-A1 | NOVEL PROCESS FOR THE PREPARATION OF CRISABOROLE AND ITS INTERMEDIATES | UGT2B17, SQLE, CYP11B1 | TSHR 4485/4885NAPRT 2236/4885TDP1 4727/4885 |
| US-20240182496-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | TALDO1, TFPI, SQLE | TSHR 3167/4885NAPRT 1717/4885TDP1 3613/4885 |
| US-11708382-B2 | Process for the preparation of highly pure Crisaborole | SQLE, UGT2B17, CYP2C19 | TSHR 4414/4885NAPRT 2675/4885TDP1 4714/4885 |
| US-20200262848-A1 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | TALDO1, TFPI, SQLE | TSHR 3167/4885NAPRT 1717/4885TDP1 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.